BioStem Technologies (BSEM) Announces Retirement of 128,979,751 Shares of Common Stock and the Issuance of Amended Series B-1

BioStem Technologies (BSEM) Announces Retirement of 128,979,751 Shares of Common Stock and the Issuance of Amended Series B-1 Convertible Stock

 

Oakland Park, FL - January 8, 2015 - InvestorsHub NewsWire - Biostem Technologies, Inc. (BSEM), announces that it has officially retired 128,979,751 shares of common stock. Furthermore, the company has amended its Series B-1 shares. The retiring of the 128,979,751 common shares to treasury reduced the total outstanding common shares by roughly 25%. We believe that by retiring the shares, the company will be better structured to move forward with it’s plans and goals.

Additionally, we would like to further report on the results of the introductions from the 22nd Annual World Congress On Anti-Aging (A4M Conference). Dr. Rafael Gonzalez, who is on the Advisory Board of BSEM, was a keynote speaker at this event, generating much new interest and introductions. We are striving to evaluate new ideas and strategies to further the growth of the company. As a result of its interaction with new people from the A4M conference, BSEM is looking forward to incorporate new innovative treatments in the Anti-Aging field both short and long term.

 

About The American Academy of Anti-Aging Medicine (A4M):

The American Academy of Anti-Aging Medicine (A4M) is a US federally registered 501(c) 3 non-profit organization comprised of over 26,000 members including: physicians, health practitioners, scientists, government officials, and members of the general pubic, representing over 110 nations.

The A4M is dedicated to the advancement of technology to detect, prevent, and treat aging related diseases and to promote research into methods to retard and optimize the human aging process. The A4M is also dedicated to educating physicians, scientist, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues.

About Biostem Technologies, Inc. (BSEM):

Biostem Technologies, Inc. is focused on helping individuals protect and ensure their future quality of life through Adult and/or Cord Blood Stem Cell Incubation and the practice of regenerative medicine in the United States and the Dominican Republic. BSEM’s mission is not only to allow patients to store their Stem Cells for future use, but also perform patient funded stem cell therapies ranging from sports injuries to degenerative diseases such as MS, Arthritis, Degenerative Heart Diseases, Diabetes and a host of experimental therapies in the brain trauma disease sector including CTE. Our goal is to become a global leader in establishing protocols that can be patented and utilized to heal patients around the world. 

Stem cells work as the repairmen of the body by replenishing and regenerating damaged tissues and cells. Certain conditions have shown marked improvement when treated with stem cells taken from the patient's own body as well as Cord Blood stem cells.

Forward-Looking Statements ?Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects,"”believe” or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

 

 

Contact:

Biostem Technologies, Inc.

Phone: [phone]

Website: http://www.biostemtech.com

Email: [e-mail]

Twitter: @Biostemtech